Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Eli Lilly plans to launch Mounjaro, an anti-diabetes and weight loss drug, in India by 2025. The medication, which is ...

The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...